Energenesis Biomedical CO.,LTD.

Equities

6657

TW0006657000

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
52.6 ^TWD	+0.57%		-2.05%	-12.91%

05-09	Energenesis Biomedical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Energenesis Biomedical CO.,LTD. announced a financing transaction	CI

Energenesis Biomedical CO.,LTD. announced that it has received TWD 9.9981 million in funding from Poalim Ventures Ltd.

October 23, 2019

Energenesis Biomedical CO.,LTD. (GTSM:6657) announced a private placement of 161,000 shares common shares at a price of TWD 62.10 for gross proceeds of TWD 9,998,100 on October 24, 2019. The transaction involved participation from Poalim Ventures Ltd.

Latest news about Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Energenesis Biomedical CO.,LTD. announced a financing transaction	04-07	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Energenesis Biomedical CO.,LTD.(TWSE:6657) added to S&P Global BMI Index	18/09/23	CI
Energenesis Biomedical CO.,LTD.(TWSE:6657) added to Taiwan TAIEX Index	07/09/23	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	18/02/23	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Energenesis Biomedical CO.,LTD.(TPEX:6657) dropped from S&P Global BMI Index	19/09/22	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2022	11/08/22	CI
Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2021	08/04/22	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	11/08/21	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	14/04/21	CI
Energenesis Biomedical CO.,LTD.(GTSM:6657) added to S&P Global BMI Index	21/09/20	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	12/08/20	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	24/03/20	CI
Energenesis Biomedical CO.,LTD. announced that it expects to receive TWD 19.9962 million in funding from SCI Pharmtech, Inc.	24/10/19	CI
Energenesis Biomedical CO.,LTD. announced that it has received TWD 9.9981 million in funding from Poalim Ventures Ltd.	23/10/19	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	12/08/19	CI
Energenesis Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	28/03/19	CI

Chart Energenesis Biomedical CO.,LTD.

Duration

Period

More charts

Company Profile

ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENERGENESIS BIOMEDICAL CO.,LTD.	-12.91%	123M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research